📊 GRI Key Takeaways
Is GRI Bio, Inc. (GRI) a Good Investment?
GRI Bio is a pre-revenue pharmaceutical company burning $3.7M annually with only $16K in revenue and -$2M operating losses. Despite $11M in cash reserves, the current burn rate depletes runway in approximately 3 years without revenue inflection or capital restructuring. Fundamental business model shows no traction and unacceptable operational risk.
GRI Bio is essentially pre-revenue with extremely negative margins and large operating losses, indicating no near-term path to profitability. While liquidity is currently adequate (strong current ratio, no debt), cash of $8.23M against a -$10.19M operating cash outflow implies a short runway and high likelihood of dilutive financing. Fundamentals are weak until the company secures non-dilutive funding or demonstrates meaningful revenue traction.
Why Buy GRI Bio, Inc. Stock? GRI Key Strengths
- Strong liquidity position with $11M cash equivalents representing 14.21x current ratio coverage
- Zero debt burden eliminates financial stress and provides capital structure flexibility
- Minimal capex requirements ($3K) and conservative balance sheet operation
- Debt-free balance sheet
- Solid current ratio with cash covering most liabilities
- Minimal capex and flexible cost base
GRI Stock Risks: GRI Bio, Inc. Investment Risks
- Pre-revenue stage with $16K revenue against $3.7M annual operating cash burn creating urgent solvency timeline
- Operating margin of -12,518.8% indicates fundamental business model execution failure
- No disclosed pipeline visibility, clinical trial progress, or commercialization milestones create uncertainty on capital deployment
- Imminent cash depletion within 3 years necessitates dilutive capital raise or asset sale
- Zero Form 4 insider filings suggest complete lack of insider confidence in company direction
- Short cash runway necessitating dilutive capital raises or cutbacks
- Severe and persistent operating losses with highly negative margins and ROE/ROA
- Lack of revenue traction heightens going-concern and execution risk
Key Metrics to Watch
- Quarterly revenue growth trajectory and acceleration toward commercial break-even
- Monthly cash burn rate trend and cash runway extension announcements
- FDA clinical trial milestone achievements and drug pipeline advancement disclosures
- Capital raise announcements and dilution impact on equity holders
- Operating cash flow improvement and path to positive cash generation
- Operating cash flow (burn rate)
- Cash & equivalents (runway months)
GRI Bio, Inc. (GRI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.21x current ratio provides a solid financial cushion.
GRI Profit Margin, ROE & Profitability Analysis
GRI vs Healthcare Sector: How GRI Bio, Inc. Compares
How GRI Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GRI Bio, Inc. Stock Overvalued? GRI Valuation Analysis 2026
Based on fundamental analysis, GRI Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GRI Bio, Inc. Balance Sheet: GRI Debt, Cash & Liquidity
GRI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GRI Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1,545.55 indicates the company is currently unprofitable.
GRI Revenue Growth, EPS Growth & YoY Performance
GRI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2022 | N/A | -$2.6M | $-0.39 |
| Q3 2021 | N/A | -$1.0M | $-0.18 |
| Q2 2021 | N/A | -$1.1M | $-0.25 |
| Q1 2021 | $100.0K | -$1.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GRI Bio, Inc. Dividends, Buybacks & Capital Allocation
GRI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GRI Bio, Inc. (CIK: 0001824293)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GRI
What is the AI rating for GRI?
GRI Bio, Inc. (GRI) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GRI's key strengths?
Claude: Strong liquidity position with $11M cash equivalents representing 14.21x current ratio coverage. Zero debt burden eliminates financial stress and provides capital structure flexibility. ChatGPT: Debt-free balance sheet. Solid current ratio with cash covering most liabilities.
What are the risks of investing in GRI?
Claude: Pre-revenue stage with $16K revenue against $3.7M annual operating cash burn creating urgent solvency timeline. Operating margin of -12,518.8% indicates fundamental business model execution failure. ChatGPT: Short cash runway necessitating dilutive capital raises or cutbacks. Severe and persistent operating losses with highly negative margins and ROE/ROA.
What is GRI's revenue and growth?
GRI Bio, Inc. reported revenue of $16.0K.
Does GRI pay dividends?
GRI Bio, Inc. does not currently pay dividends.
Where can I find GRI SEC filings?
Official SEC filings for GRI Bio, Inc. (CIK: 0001824293) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GRI's EPS?
GRI Bio, Inc. has a diluted EPS of $-1.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GRI a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, GRI Bio, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GRI stock overvalued or undervalued?
Valuation metrics for GRI: ROE of -18.9% (sector avg: 15%), net margin of -12,487.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GRI stock in 2026?
Our dual AI analysis gives GRI Bio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GRI's free cash flow?
GRI Bio, Inc.'s operating cash flow is $-3.7M, with capital expenditures of $3.0K. FCF margin is -23,050.0%.
How does GRI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -12,487.5% (avg: 12%), ROE -18.9% (avg: 15%), current ratio 14.21 (avg: 2).